|
US2021106575A1
|
|
Method of treatment of schizophrenia
|
|
WO2021003086A1
|
|
Tasimelteon use in treating sleep aberrations
|
|
WO2020168056A1
|
|
Method of improving sleep
|
|
US2020171018A1
|
|
Depot administration of iloperidone
|
|
WO2020132513A1
|
|
Improved treatment of atopic dermatitis with tradipitant
|
|
WO2020117901A1
|
|
Depot administration of iloperidone
|
|
WO2020117811A1
|
|
Method of treatment with tradipitant
|
|
US2020101045A1
|
|
Use of tradipitant in motion sickness
|
|
AU2019348001A1
|
|
Use of tradipitant in motion sickness
|
|
CA3112202A1
|
|
Improving sleep or post-sleep performance
|
|
US2020071750A1
|
|
Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
|
|
SG11202007642RA
|
|
Treatment of disorders with tasimelteon
|
|
US2019133991A1
|
|
Treatment of circadian rhythm disorders
|
|
CN111343981A
|
|
Methods of treating gastrointestinal disorders using dapipristan
|
|
KR20200054232A
|
|
Improved treatment of atopic dermatitis with tradipitant
|
|
WO2019028245A1
|
|
Use of tasimelteon for the treatment of affective disorders
|
|
US2020397765A1
|
|
Method for improving or enhancing cognition
|
|
US2017165222A1
|
|
Method of treatment
|
|
US2017165250A1
|
|
Treatment of schizophrenia
|
|
AU2016202001A1
|
|
Melatonin agonist treatment
|
